Oncolytics Biotech (NASDAQ:ONCY) Director Purchases $21,250.00 in Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Deborah Margaret Brown purchased 25,000 shares of the stock in a transaction on Thursday, February 12th. The stock was acquired at an average price of $0.85 per share, with a total value of $21,250.00. Following the completion of the acquisition, the director directly owned 109,851 shares of the company’s stock, valued at approximately $93,373.35. This represents a 29.46% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Oncolytics Biotech Price Performance

NASDAQ ONCY opened at $0.83 on Friday. Oncolytics Biotech Inc. has a one year low of $0.33 and a one year high of $1.51. The firm has a market cap of $88.60 million, a P/E ratio of -2.98 and a beta of 0.99. The stock’s 50-day moving average is $0.98 and its 200-day moving average is $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. Equities analysts anticipate that Oncolytics Biotech Inc. will post -0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. Zacks Research upgraded Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Finally, HC Wainwright increased their price objective on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Oncolytics Biotech currently has a consensus rating of “Moderate Buy” and an average target price of $6.25.

Institutional Investors Weigh In On Oncolytics Biotech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONCY. Citadel Advisors LLC bought a new stake in Oncolytics Biotech during the 3rd quarter worth about $535,000. Tocqueville Asset Management L.P. acquired a new stake in shares of Oncolytics Biotech in the fourth quarter valued at about $63,000. CIBC Private Wealth Group LLC bought a new stake in Oncolytics Biotech during the fourth quarter worth about $44,000. Scientech Research LLC acquired a new position in Oncolytics Biotech during the third quarter valued at approximately $25,000. Finally, Ground Swell Capital LLC bought a new position in Oncolytics Biotech in the fourth quarter valued at approximately $30,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.